Goldman Sachs
KYTX icon

Goldman Sachs’s Kyverna Therapeutics KYTX Stock Holding History

Goldman Sachs’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.99M Buy
335,230
+122,320
+57% +$1.09M ﹤0.01% 4348
2026
Q1 		$1.84M Buy
212,910
+79,380
+59% +$661K ﹤0.01% 4616
2025
Q4 		$1.26M Buy
133,530
+90,398
+210% +$671K ﹤0.01% 4960
2025
Q3 		$259K Sell
43,132
-93,246
-68% -$373K ﹤0.01% 5836
2025
Q2 		$419K Buy
136,378
+31,918
+31% +$78.9K ﹤0.01% 5257
2025
Q1 		$202K Sell
104,460
-9,014
-8% -$26.6K ﹤0.01% 5641
2024
Q4 		$424K Buy
113,474
+33,671
+42% +$161K ﹤0.01% 5333
2024
Q3 		$390K Buy
79,803
+17,513
+28% +$135K ﹤0.01% 5187
2024
Q2 		$467K Buy
+62,290
New +$952K ﹤0.01% 4872

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Goldman Sachs's KYTX Position: Q2 2026 in Review

Goldman Sachs increased its Kyverna Therapeutics (KYTX) stake by 57% in Q2 2026, buying an estimated $1.09M and bringing the position to 335,230 shares worth $2.99M. The position accounts for ﹤0.01% of the portfolio, ranked #4348.

Goldman Sachs first reported a position in KYTX in Q2 2024 and has held it in 9 quarters since. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Goldman Sachs held 335,230 shares of Kyverna Therapeutics worth $2.99M as of Q2 2026.
  • Goldman Sachs bought 122,320 Kyverna Therapeutics shares in Q2 2026, an estimated $1.09M.
  • Kyverna Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4348 holding.
  • Goldman Sachs first reported a position in Kyverna Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.